AUA: Immunotherapy Aids Survival in Muscle - Invasive Bladder Cancer
Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Conferences | HIV AIDS | Immunotherapy | Urology & Nephrology